Abbott's market-leading drug-eluting stent (DES) Xience V has surpassed Taxus Express2, a rival device marketed by Boston Scientific, in a clinical trial. One-year data from the SPIRIT IV trial demonstrated that the everolimus-eluting Xience V achieved superiority over Taxus in the ...
Please Login to read the full article.
